---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-031834"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-09-19T23:59:59+00:00"
generated_at: "2026-06-23T08:48:55.726680+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Trevi reports positive Phase 2 CANAL data: Haduvio reduces daytime cough 75% vs 23% placebo

## Summary
- Primary endpoint met: placebo-adjusted daytime cough frequency reduction 52.5% (p<0.0001).
- Haduvio achieved 76.1% reduction in 24-hour cough frequency vs 25.3% placebo (p<0.0001).
- 97% of Haduvio subjects had ≥30% reduction in 24-hour cough vs 35% placebo (p<0.0001).
- Company aims to initiate Phase 2b in chronic cough IPF in H1 2023, Phase 3 in prurigo nodularis in H1 2023.
- Safety consistent with prior trials; most common adverse events: nausea, fatigue, constipation, dizziness.

## SEC filing metadata
- accession: 0001564590-22-031834
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022031834/0001564590-22-031834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022031834/trvi-8k_20220919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-031834
- JSON: https://secwatch.observer/filing/0001564590-22-031834.json
- Plain text: https://secwatch.observer/filing/0001564590-22-031834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.